Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02112994 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of Sebelipase Alfa in Participants With Lysosomal Acid Lipase Deficiency
A Phase 2 study of Lysosomal Acid Lipase Deficiency, sponsored by Alexion Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 31
- Enrollment target
- 19
- Study locations
NCT02112994 is a Phase 2 study of Lysosomal Acid Lipase Deficiency that has completed, run by Alexion Pharmaceuticals. The registered enrollment target is 31 participants. The trial reports 19 study locations across 5 states.
The verdict
NCT02112994, a Phase 2 study of Lysosomal Acid Lipase Deficiency, has completed, sponsored by Alexion Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 31 participants
- Enrollment target
- 19
- Study locations
Study Summary
This study evaluated the safety and efficacy of sebelipase alfa in a broad population of participants with lysosomal acid lipase deficiency (LAL-D).
Conditions Studied
Interventions
- DRUG Sebelipase Alfa
Study Locations (19)
Other
- - Westmead
- - Brussels
- - São Paulo
- - Zagreb
- - Copenhagen
- - Freiburg im Breisgau
- - Padua
- - Mexico City
- - Amsterdam
- - Moscow
- - A Coruña
- - Barcelona
- - Madrid
- - Balcalı
- - Birmingham
Illinois
- - Chicago
Louisiana
- - Shreveport
Ohio
- - Cincinnati
Nova Scotia
- - Halifax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2014-06-24 |
| Est. Completion | 2017-12-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02112994
The ClinicalTrials.gov registry entry for NCT02112994 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alexion Pharmaceuticals, which has 162 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lysosomal Acid Lipase Deficiency appearing as the primary indexed condition, and to 1 intervention - of which Sebelipase Alfa is the first listed.
NCT02112994 reports 19 study locations spanning 5 distinct geographic areas - top geographies include Other, Illinois, Louisiana.
Frequently Asked Questions
What is clinical trial NCT02112994 about?
NCT02112994 is a clinical study titled "Safety and Efficacy Study of Sebelipase Alfa in Participants With Lysosomal Acid Lipase Deficiency". This study evaluated the safety and efficacy of sebelipase alfa in a broad population of participants with lysosomal acid lipase deficiency (LAL-D).
What is the current status of trial NCT02112994?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 31 participants. The study started on 2014-06-24. Estimated completion is 2017-12-28.
What conditions does trial NCT02112994 study?
This clinical trial studies the following conditions: Lysosomal Acid Lipase Deficiency.
What interventions are being tested in trial NCT02112994?
The interventions under investigation include: Sebelipase Alfa (DRUG).
Who is sponsoring clinical trial NCT02112994?
This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02112994 being conducted?
This trial has 19 study locations across Illinois, Louisiana, Ohio, Nova Scotia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lysosomal Acid Lipase Deficiency
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.